HCP
XENE icon

Hexagon Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Hexagon Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6
Closed -$235 – 1947
2024
Q4 		$235 Buy
+6
New +$248 ﹤0.01% 1757
2023
Q4 		– Sell
-10
Closed -$342 – 1515
2023
Q3 		$342 Sell
10
-72
-88% -$2.69K ﹤0.01% 1308
2023
Q2 		$3.16K Hold
82
– – ﹤0.01% 994
2023
Q1 		$2.94K Sell
82
-27
-25% -$997 ﹤0.01% 987
2022
Q4 		$4.3K Sell
109
-88
-45% -$3.21K ﹤0.01% 942
2022
Q3 		$7K Buy
+197
New +$7.08K ﹤0.01% 870

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Hexagon Capital Partners's XENE Position: Q1 2025 in Review

Hexagon Capital Partners sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 6 shares — an estimated $235 sold.

Hexagon Capital Partners first reported a position in XENE in Q3 2022 and held it in 6 quarters. The position peaked at $7K in Q3 2022. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Hexagon Capital Partners reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 6 Xenon Pharmaceuticals shares in Q1 2025, an estimated $235.
  • Hexagon Capital Partners first reported a position in Xenon Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Hexagon Capital Partners's Xenon Pharmaceuticals position peaked at $7K in Q3 2022.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Hexagon Capital Partners's 13F filing for Q1 2025, filed 29 Apr 2025.